BALTIMORE, Feb. 3 /PRNewswire/ -- FASgen, Inc. is pleased to announce the award and issuance of the European Patent for its index compound C-75 and related weight loss claims, “Inhibition of Fatty Acid Synthase As a Means to Reduce Adipocyte Mass.” The inhibition of fatty acid synthase as a means to control obesity has been a cornerstone of FASgen’s extensive research into therapeutics to treat obesity. In parallel, the Company also announces the award and issuance of its Eurasian Patent, “Stimulation of CPT-1 as a Means to Reduce Weight.” Stimulation of CPT-1 has been demonstrated to regulate fatty acid oxidation and the consequent weight loss that follows. FASgen’s compounds have been shown to work at both the inhibition of FAS and the stimulation of CPT-1, producing significant weight loss without any perceived adverse side effects in extensive preclinical studies.
In addition to the significant enhancement of its patent portfolio, FASgen is also pleased to announce it has received a $500,000 investment from a new private equity investor. “We are extremely pleased with the progress at the Company and that this progress is marked by international recognition of our intellectual property rights,” said Albert H. Owens, Jr., M.D., President and Founder. He added, “The fact that we received an unsolicited private equity investment from a sophisticated investor is perhaps the most compelling testimony in support of our progress.”
About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 13 years of research in the field, which research continues under a sponsored research agreement with the University. The Company has designed and synthesized many compounds that selectively act on fatty acid biosynthesis targets. In addition to the anti-obesity compounds, one other group of the Company’s proprietary compounds holds great promise for new and highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one-third of the world’s population. For more information, visit FASgen’s website at http://www.fasgen.com.
Contact: Pam Spangler, FASgen, Inc., by phone at 410-559-9200, or email at Pamela.spangler@fasgen.com.
FASgen, Inc.
CONTACT: Pam Spangler, FASgen, Inc., +1-410-559-9200, orPamela.spangler@fasgen.com
Web site: http://www.fasgen.com/
